Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 94. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
The enduring decision-making role of the surgeon in the multidisciplinary management of GIST816
LBA13 Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP 772
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gast761
Important news on nutritional support in cancer patients – but some EFFORT is still ahead703
Editorial Board595
Table of Contents587
130P Oxaliplatin immune-induced syndrome (OIIS): A potentially life-threatening complication in colorectal cancer (CRC) patients (pts)572
Letter to the editor regarding ‘Misclassified confounders in the second interim analysis of the MAGNITUDE trial’ by P. Chen, M. Liu, G.Y. Li, F. Sun, T. Li535
Editorial Board524
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial464
Long-term outcomes in the PRIMA trial: a closer look at progression-free survival and overall survival373
Sensitivity of a blood ctDNA-based multimodal test for the detection of advanced colorectal neoplasms365
Editorial Board356
287P Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer352
281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: A meta-analysis of ra348
Table of Contents345
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy335
373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) tre330
244MO A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)316
362P CYBERNEO trial: Update of results at 14 years of follow-up300
331P miR-21 and miR-34a as biomarkers of radiotherapy skin adverse events in ductal carcinoma in situ289
325P Impact of breast tumour location on axillary nodal involvement, chemotherapy use, and survival285
299P Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer275
288P Prognostic factors in nonmetastatic HER2 ‘low’ & HER2 ‘negative’ breast cancer: Single institute experience273
328P Frequency of radiotherapy-induced malignancies in Li-Fraumeni syndrome patients with early breast cancer and influence of the radiotherapy technique260
291P Prognostic implications of HER2 gain in patients with HR+/HER2- breast cancer (BC) and TNBC after neoadjuvant chemotherapy (NAC)257
LBA76 The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ram254
2185TiP Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity253
1876P Cancer stigma: How Tunisian patients perceive their cancer252
1874P Beliefs about chemotherapy in Tunisian patients newly diagnosed with cancer250
352TiP Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial249
194P Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study248
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcome246
197P Clinical benefit of HER2-targeted therapies versus prior chemotherapy in refractory HER2 expressing and mutant gastrointestinal malignancies236
213P Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway226
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study200
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study198
LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: Results from the DISCO randomized trial197
191P Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment193
1867P A cross-sectional examination of information disclosure and health literacy amongst patients with lymphoma190
226P LongiBloodImmunoM: A multi-step analysis pipeline for longitudinal blood-based immunomonitoring for immunotherapy clinical trial190
LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047188
210P Lung tumour vascularity is a risk factor for survival in NSCLC patients undergoing surgery186
649P The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)185
1880P Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico176
LBA91 TOMAS2: A randomized phase II study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS)167
1258P Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?162
196P Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts159
LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas159
222P Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer158
LBA82 Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HE157
1179P The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients155
ESMO153
LBA95 Anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia: Efficacy and safety in the multinational phase III SCALA program153
LBA90 A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS-0415)150
1138P Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity149
1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 2149
1237P Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor147
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi144
1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)143
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma143
1245P A lymph nodal staging assessment model for various histologic types of small intestinal tumors141
1060P Balance of CD36+ and CD16+ monocytes controls TLR-mediated cytokine release syndrome and MHC-dependent antitumor responses in EpCAM CAR T cell therapy for gastrointestinal cancers140
1149P Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment135
1227P Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer134
1317MO Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)132
1132P Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy132
1124P IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy: A deep biomarker analysis129
1142P Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems126
1352P Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC125
1334P Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency124
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?122
1407P Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort122
1364P ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)118
1240P Multi-centric validation of an AI-based sTIL% scoring model for breast cancer H&E whole-slide images118
1158P Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)117
1232P Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification112
1207O Beyond 100,000 genomes project: Whole genome sequencing for cancer patients within NHS Genomic Medicine Service112
1456P Exploring biological and molecular factors as outcome predictors for pembrolizumab (Pem) or pembrolizumab-chemotherapy (Pem-CT) in advanced non-small cell lung cancer (NSCLC)111
1418P Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study108
1642P Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients106
1357P Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy105
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)103
1403P Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program103
1488P Exploring efficacy and safety of immune checkpoint inhibitors (ICI) in extensive stage (ES)- small-cell lung cancer (SCLC) in specific populations: Real-world data from the Durvalumab Expanded A102
1367P Predictive clinical characteristics for body weight gain in patients treated with alectinib: Analyses of J-ALEX, ALUR, and ML29453100
1249P Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data99
1387P Efficacy of first-line treatment options in advanced HER2-altered non-small cell lung cancer: A multi-center retrospective study98
1354P Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations98
1462P Phase Ia study of MIDRIX4-LUNG, a quadrivalent autologous dendritic cell immunotherapy, in patients with metastatic non-small cell lung cancer98
1868P Challenges for shared decision making in incurable cancer, with a focus on health literacy96
375TiP A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors95
139P The characteristics in Chinese NSCLC patients with different BRAF mutation classes95
135P The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)95
1205TiP Camrelizumab combined with EP/EC chemotherapy followed by camrelizumab plus apatinib for first-line therapy of advanced extrapulmonary neuroendocrine carcinoma: A prospective, single-arm, mult94
0.044815063476562